Search alternatives:
significant levels » significant level (Expand Search), significance levels (Expand Search), significance level (Expand Search)
significant linear » significant clinical (Expand Search), significant level (Expand Search), significant gender (Expand Search)
linear decrease » linear increase (Expand Search)
Showing 61 - 80 results of 75,657 for search '(( significant levels increased ) OR ( significant linear decrease ))*', query time: 0.85s Refine Results
  1. 61
    Spearman correlation matrix analysis of the RAAS system and glucose metabolism indexes at different hypertension subgroups.

    Spearman correlation matrix analysis of the RAAS system and glucose metabolism indexes at different hypertension subgroups. by Ningning Wang (560944)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 62
    General characterization of T2DM patients and healthy controls.

    General characterization of T2DM patients and healthy controls. by Ningning Wang (560944)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 63
    Antihypertensive treatment of 151 T2DM patients with hypertension at different subgroups.

    Antihypertensive treatment of 151 T2DM patients with hypertension at different subgroups. by Ningning Wang (560944)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 64
    Spearman correlation matrix analysis of the RAAS system and glucose metabolism indexes at different normotension subgroups.

    Spearman correlation matrix analysis of the RAAS system and glucose metabolism indexes at different normotension subgroups. by Ningning Wang (560944)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 65
    Spearman correlation matrix analysis of the RAAS system and glucose metabolism indexes in hypertensive (A) and normotensive (B) patients.

    Spearman correlation matrix analysis of the RAAS system and glucose metabolism indexes in hypertensive (A) and normotensive (B) patients. by Ningning Wang (560944)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 66
    AZ10606120 treatment significantly increased cytotoxicity and reduced cell number in a dose-dependent manner.

    AZ10606120 treatment significantly increased cytotoxicity and reduced cell number in a dose-dependent manner. by Matthew Drill (22258391)

    Published 2025
    “…<b>(b)</b> Cytotoxicity quantified via LDH assay of U251 culture supernatants post-treatment. LDH levels were significantly increased in culture supernatants treated with AZ10606120 (50µM) compared to temozolomide (50µM) treatment and untreated controls. …”
    Save to List
    Saved in:
  7. 67
    Multiple linear regression analysis of the RAAS and glucose metabolism indicators before and after treatment in DKD and non-DKD patients.

    Multiple linear regression analysis of the RAAS and glucose metabolism indicators before and after treatment in DKD and non-DKD patients. by Ningning Wang (560944)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 68
    List of the proteins that increased or decreased significantly with the progression of liver fibrosis.

    List of the proteins that increased or decreased significantly with the progression of liver fibrosis. by Kumiko Shirai (13014884)

    Published 2022
    Save to List
    Saved in:
  9. 69
    The scatterplot, linear regression equation, 95% confidence band, and <i>p</i>-value for the oxidation-reduction potential (ORP) in millivolts (mV) versus pH.

    The scatterplot, linear regression equation, 95% confidence band, and <i>p</i>-value for the oxidation-reduction potential (ORP) in millivolts (mV) versus pH. by Seth H. Frisbie (7821866)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 70
    The scatterplot, linear regression equation, 95% confidence band, and <i>p</i>-value for the concentration of arsenic (As) in micrograms per liter (μg/L) versus pH.

    The scatterplot, linear regression equation, 95% confidence band, and <i>p</i>-value for the concentration of arsenic (As) in micrograms per liter (μg/L) versus pH. by Seth H. Frisbie (7821866)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 71
    Statistically significant linear increase in use of antidementia medications and antipsychotics during the observed time period.

    Statistically significant linear increase in use of antidementia medications and antipsychotics during the observed time period. by Jelena Filimonovic (22305307)

    Published 2025
    Save to List
    Saved in:
  12. 72
    Statistically significant linear decrease in use of antidepressants, antipsychotics, psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics during the observed time period.

    Statistically significant linear decrease in use of antidepressants, antipsychotics, psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics during the observed time period. by Jelena Filimonovic (22305307)

    Published 2025
    Save to List
    Saved in:
  13. 73
    The scatterplot, linear regression equation, 95% confidence band, and <i>p</i>-value for the concentration of arsenic (As) in micrograms per liter (μg/L) versus temperature (T) in Celsius (°C).

    The scatterplot, linear regression equation, 95% confidence band, and <i>p</i>-value for the concentration of arsenic (As) in micrograms per liter (μg/L) versus temperature (T) in... by Seth H. Frisbie (7821866)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 74
    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  15. 75
    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  16. 76
    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  17. 77
    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  18. 78
    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  19. 79
    Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  20. 80
    Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:

Search Tools: